Change in lifestyle and drug intervention: Prevention of diabetes mellitus type 2;Lebensstiländerung und medikamentöse intervention: Prävention des diabetes mellitus typ 2

Notfall und Hausarztmedizin

Volumn 31, Issue 1-2, 2005, Pages 20-27

  Schwarz, Peter E H ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; METFORMIN; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TROGLITAZONE;

ADULT; AGED; BEHAVIOR MODIFICATION; CLINICAL TRIAL; DISEASE PREDISPOSITION; EVIDENCE BASED MEDICINE; GLUCOSE TOLERANCE; HUMAN; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; REVIEW; SOCIOECONOMICS;

EID: 14344252203     PISSN: 16128591     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864643     Document Type: Review

References (35)

1. Organization WH. Prevention of Diabetes mellitus - Report of a WHO Study Group. WHO Technical Report Series, 1994. WHO Technical Report Series 844 (ISBN 9241208449)
2. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414 (6865): 782-787
3. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108 (13): 1541-1545
4. Rathmann W et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA survey 2000. Diabetologia 2003; 46 (2): 182-189
5. IDF. W.C.o.D.P.i.H.K. - Call for Action Statement - Primary Prevention of Type 2 Diabetes - Setting up the International and National Action Plans, 2002
6. Schneider H, Lischinski M, Jutzi E. Prognosis of diabetic patients in Northeast Germany. Z Arztl Fortbild 1994; 88 (11): 925-930
7. Schneider H, Lischinski M, Jutzi E. Survival of diabetic patients at 30-year follow-up with reference to a closed population. Z Arztl Fortbild 1993; 87 (4): 323-327
8. Haffner SM. Can reducing peaks prevent type 2 diabetes: implication from recent diabetes prevention trials. Int J Clin Pract Suppl 2002 (129): 33-39
9. Liebl A et al. Costly type 2 diabetes mellitus. Does diabetes cost 20 billion per year?. MMW Fortschr Med 2000; 142 (23): 39-42
10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352 (9131): 837-853
11. UK Prospective Diabetes Study (UKPDS), XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 1994; 11 (6): 534-544
12. Haffner SM et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101 (9): 975-980
13. Fontbonne A et al. Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus: the Paris Prospective Study, 15-year follow-up. Diabetologia 1992; 35 (5): 464-468
14. Fagot-Campagna A, Narayan KM, Imperatore G. Type 2 diabetes in children. Bmj 2001; 322 (7283): 377-378
15. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003; 26 (9): 2518-2523
16. Zimmet P, Shaw J, Alberti KG. Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 2003; 20 (9): 693-702
17. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346 (6): 393-403
18. Tuomilehto J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344 (18): 1343-1350
19. Chiasson JL et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359 (9323): 2072-2077
20. Pan XR et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20 (4): 537-44
21. Lindstrom J, Tuomilehto J. The Diabetes Risk Score: A practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26 (3): 725-731
22. Engelgau MM, Venkat Narayan KM, Vinicor F. Identifying the target population for primary prevention: the trade-offs. Diabetes Care 2002; 25(11): 2098-2099
23. Eriksson J et al. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland, Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999; 42 (7): 793-801
24. Molitch ME et al. The diabetes prevention program and its global implications. J Am Soc Nephrol 2003; 14 (7 Suppl 2): 103-107
25. Wenying Y. Chin. J. Endocrinol. Metab. 2001; 3 (3): 131-136
26. Standl E. Metformin: drug of choice for the prevention of type 2 diabetes and cardiovascular complications in high-risk subjects. Diabetes Metab 2003; 29 (4 Pt 2): 121-122
27. Chiasson JL et al. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus, Diabetes Care 1998; 21 (10): 1720-1725
28. Torgerson JS et al. XENical in the prevention of Diabetes in Obese Subjects (XEN-DOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27 (1): 155-161
29. Reaven C et al. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001; 87 (7): 827-831
30. Azen SP et al. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, Plazebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998; 19 (2): 217-231
31. Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003; 63 (10): 933-951
32. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26 (4): 977-980
33. Buchanan TA. Preventing, delaying, or masking type 2 diabetes with metformin in the diabetes prevention program?: response to scheen. Diabetes Care 2003; 26 (9): 2701-2702
34. Hernan WH et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care, 2003, 26 (1): 36-47
35. Schwarz P et al. Gründung der "Arbeitsgemeinschaft Prävention des Typ-2-Diabetes" der DDG. Diabetes und Stoffwechsel 2003, 12 (5): 296-274